The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy.

Trial Profile

The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2015

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Cardiomyopathies; Heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 15 Jun 2011 Company (Pfizer) added in the association field as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Planned number of patients changed from 20 to 40, based on information from ClinicalTrials.gov.
    • 08 Oct 2008 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top